{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T20:31:46Z","timestamp":1761597106244},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2008,10,8]],"date-time":"2008-10-08T00:00:00Z","timestamp":1223424000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurochem Res"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1007\/s11064-008-9851-1","type":"journal-article","created":{"date-parts":[[2008,10,7]],"date-time":"2008-10-07T01:41:23Z","timestamp":1223343683000},"page":"917-922","source":"Crossref","is-referenced-by-count":16,"title":["Plasma Homovanillic Acid and Prolactin in Huntington\u2019s Disease"],"prefix":"10.1007","volume":"34","author":[{"given":"Manolis","family":"Markianos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marios","family":"Panas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikos","family":"Kalfakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Vassilopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,10,8]]},"reference":[{"key":"9851_CR1","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1074\/jbc.273.6.3756","volume":"273","author":"Y Luo","year":"1998","unstructured":"Luo Y, Umegaki H, Wang X et al (1998) Dopamine induces apoptosis through an oxidation-involved SAPK\/JNK activation pathway. J Biol Chem 273:3756\u20133764. doi: 10.1074\/jbc.273.6.3756","journal-title":"J Biol Chem"},{"key":"9851_CR2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0166-2236(00)01568-X","volume":"23","author":"RJ Jakel","year":"2000","unstructured":"Jakel RJ, Maragos WE (2000) Neuronal cell death in Huntington\u2019s disease: a potential role for dopamine. Trends Neurosci 23:239\u2013245. doi: 10.1016\/S0166-2236(00)01568-X","journal-title":"Trends Neurosci"},{"key":"9851_CR3","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1093\/hmg\/10.12.1243","volume":"10","author":"A Petersen","year":"2001","unstructured":"Petersen A, Larsen KE, Behr GG et al (2001) Expanded CAG repeats in exon 1 of the Huntington\u2019s disease gene stimulate dopamine-mediated striatal neuron autophagy and degeneration. Hum Mol Genet 10:1243\u20131254. doi: 10.1093\/hmg\/10.12.1243","journal-title":"Hum Mol Genet"},{"key":"9851_CR4","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/syn.890020511","volume":"2","author":"JN Joyce","year":"1988","unstructured":"Joyce JN, Lexow N, Bird E et al (1988) Organization of dopamine D1 and D2 receptors in human striatum: receptor autoradiographic studies in Hubtington\u2019s disease and schizophrenia. Synapse 2:546\u2013557. doi: 10.1002\/syn.890020511","journal-title":"Synapse"},{"key":"9851_CR5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1176\/jnp.2.1.20","volume":"2","author":"J Brandt","year":"1990","unstructured":"Brandt J, Folstein SE, Wong DF et al (1990) D2 receptors in Huntington\u2019s disease: positron emission tomography findings and clinical correlates. J Neuropsychiatry Clin Neurosci 2:20\u201327","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"9851_CR6","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0304-3940(91)90448-3","volume":"132","author":"EK Richfield","year":"1991","unstructured":"Richfield EK, O\u2019Brien CF, Eskin T et al (1991) Heterogeneous dopamine receptor changes in early and late Huntington\u2019s disease. Neurosci Lett 132:121\u2013126. doi: 10.1016\/0304-3940(91)90448-3","journal-title":"Neurosci Lett"},{"key":"9851_CR7","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/brain\/120.3.503","volume":"120","author":"N Ginovart","year":"1997","unstructured":"Ginovart N, Lundin A, Farde L et al (1997) PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington\u2019s disease. Brain 120:503\u2013514. doi: 10.1093\/brain\/120.3.503","journal-title":"Brain"},{"key":"9851_CR8","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1093\/brain\/122.12.2353","volume":"122","author":"TC Andrews","year":"1999","unstructured":"Andrews TC, Weeks RA, Turjanski N et al (1999) Huntington\u2019s disease progression. PET and clinical observations. Brain 122:2353\u20132363. doi: 10.1093\/brain\/122.12.2353","journal-title":"Brain"},{"key":"9851_CR9","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1126\/science.6449080","volume":"210","author":"JJ Mann","year":"1980","unstructured":"Mann JJ, Stanley M, Gershon S et al (1980) Mental symptoms in Huntington\u2019s disease and a possible primary aminergic neuron lesion. Science 210:1369\u20131371. doi: 10.1126\/science.6449080","journal-title":"Science"},{"key":"9851_CR10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/BF01256491","volume":"65","author":"GP Reynolds","year":"1986","unstructured":"Reynolds GP, Garrett NJ (1986) Striatal dopamine and homovanillic acid in Huntington\u2019s disease. J Neural Transm 65:151\u2013155. doi: 10.1007\/BF01256491","journal-title":"J Neural Transm"},{"key":"9851_CR11","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/ana.410220318","volume":"22","author":"SJ Kish","year":"1987","unstructured":"Kish SJ, Shannak K, Hornykiewicz O (1987) Elevated serotonin and reduced dopamine in subregionally divided Huntington\u2019s disease striatum. Ann Neurol 22:386\u2013389. doi: 10.1002\/ana.410220318","journal-title":"Ann Neurol"},{"key":"9851_CR12","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1136\/jnnp.35.4.514","volume":"35","author":"G Curzon","year":"1972","unstructured":"Curzon G, Gumpert J, Sharpe D (1972) Amine metabolites in the cerebrospinal fluid in Huntington\u2019s chorea. J Neurol Neurosurg Psychiatry 35:514\u2013519","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9851_CR13","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00002826-199502000-00007","volume":"18","author":"PJ Garcia Ruiz","year":"1995","unstructured":"Garcia Ruiz PJ, Mena MA, Sanchez Bernardos V et al (1995) Cerebrospinal fluid homovanillic acid is reduced in untreated Huntington\u2019s disease. Clin Neuropharmacol 18:58\u201363. doi: 10.1097\/00002826-199502000-00007","journal-title":"Clin Neuropharmacol"},{"key":"9851_CR14","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/ana.410240221","volume":"24","author":"R Kurlan","year":"1988","unstructured":"Kurlan R, Godblatt D, Zaczek R et al (1988) Cerebrospinal fluid homovanillic acid and parkinsonism in Huntington\u2019s disease. Ann Neurol 24:282\u2013284. doi: 10.1002\/ana.410240221","journal-title":"Ann Neurol"},{"key":"9851_CR15","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/BF00711243","volume":"8","author":"IJ Kopin","year":"1988","unstructured":"Kopin IJ, White JH, Bankiewicz K (1988) A new approach to biochemical evaluation of brain dopamine metabolism. Cell Mol Neurobiol 8:171\u2013179. doi: 10.1007\/BF00711243","journal-title":"Cell Mol Neurobiol"},{"key":"9851_CR16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/schbul\/18.1.123","volume":"18","author":"F Amin","year":"1992","unstructured":"Amin F, Davidson M, Davis KL (1992) Homovanillic acid measurements in clinical research: a review of methodology. Schizophr Bull 18:123\u2013148","journal-title":"Schizophr Bull"},{"key":"9851_CR17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/schbul\/21.1.53","volume":"21","author":"F Amin","year":"1995","unstructured":"Amin F, Davidson M, Kahn RS et al (1995) Assessment of the central dopaminergic index of plasma HVA in schizophrenia. Schizophr Bull 21:53\u201366","journal-title":"Schizophr Bull"},{"key":"9851_CR18","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/0024-3205(91)90593-Z","volume":"49","author":"GW Lambert","year":"1991","unstructured":"Lambert GW, Eisenhofer G, Cox HS et al (1991) Direct determination of homovanillic acid release from the human brain, an indicator of central dopaminergic activity. Life Sci 49:1061\u20131072. doi: 10.1016\/0024-3205(91)90593-Z","journal-title":"Life Sci"},{"key":"9851_CR19","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1126\/science.3975630","volume":"227","author":"KL Davis","year":"1985","unstructured":"Davis KL, Davidson M, Mohs RC et al (1985) Plasma homovanillic acid concentrations and the severity of schizophrenic illness. Science 227:1601\u20131602. doi: 10.1126\/science.3975630","journal-title":"Science"},{"key":"9851_CR20","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1001\/archpsyc.1986.01800070059008","volume":"43","author":"D Pickar","year":"1986","unstructured":"Pickar D, Labarka R, Doran AR et al (1986) Longitudinal measurements of plasma homovanillic acid levels in schizophrenic patients. Correlations with psychosis and response to neuroleptic treatment. Arch Gen Psychiatry 43:669\u2013676","journal-title":"Arch Gen Psychiatry"},{"key":"9851_CR21","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1001\/archpsyc.1988.01800300060007","volume":"45","author":"R Davila","year":"1988","unstructured":"Davila R, Manero E, Zumarraga M et al (1988) Plasma homovanillic acid as a predictor of response to neuroleptics. Arch Gen Psychiatry 45:564\u2013566","journal-title":"Arch Gen Psychiatry"},{"key":"9851_CR22","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/0006-3223(90)90442-5","volume":"27","author":"WH Chang","year":"1990","unstructured":"Chang WH, Chen TY, Lin SK et al (1990) Plasma catecholamine metabolites in schizophrenics: evidence for two-subtype concept. Biol Psychiatry 27:510\u2013518. doi: 10.1016\/0006-3223(90)90442-5","journal-title":"Biol Psychiatry"},{"key":"9851_CR23","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/0006-3223(94)91174-6","volume":"36","author":"E Suzuki","year":"1994","unstructured":"Suzuki E, Kanba S, Nibuya M et al (1994) Longitudinal changes in symptoms and plasma homovanillic acid levels in chronically medicated schizophrenic patients. Biol Psychiatry 36:654\u2013661. doi: 10.1016\/0006-3223(94)91174-6","journal-title":"Biol Psychiatry"},{"key":"9851_CR24","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0006-3223(96)00244-2","volume":"41","author":"S Nagaoka","year":"1997","unstructured":"Nagaoka S, Iwamoto N, Arai H (1997) First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol. Biol Psychiatry 41:857\u2013864. doi: 10.1016\/S0006-3223(96)00244-2","journal-title":"Biol Psychiatry"},{"key":"9851_CR25","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0006-3223(97)00550-7","volume":"45","author":"JA Posener","year":"1999","unstructured":"Posener JA, Schatzberg AF, Williams GH et al (1999) Hypothalamic-pituitary-adrenal axis effects on plasma homovanillic acid in man. Biol Psychiatry 45:222\u2013228. doi: 10.1016\/S0006-3223(97)00550-7","journal-title":"Biol Psychiatry"},{"key":"9851_CR26","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00213-004-1924-5","volume":"177","author":"T Sumyyoshi","year":"2004","unstructured":"Sumyyoshi T, Roy A, Kim C-H et al (2004) Prediction of changes in memory performance by plasma homovanillic acid levels in clozapine-treated patients with schizophrenia. Psychopharmacology (Berl) 177:79\u201383. doi: 10.1007\/s00213-004-1924-5","journal-title":"Psychopharmacology (Berl)"},{"key":"9851_CR27","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/j.neuropsychologia.2006.12.015","volume":"45","author":"AC Solomon","year":"2007","unstructured":"Solomon AC, Stout JC, Johnson SA et al (2007) Verbal episodic memory declines prior to diagnosis in Huntington\u2019s disease. Neuropsychologia 45:1767\u20131776. doi: 10.1016\/j.neuropsychologia.2006.12.015","journal-title":"Neuropsychologia"},{"key":"9851_CR28","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0006-3223(97)00146-7","volume":"42","author":"RA Sweet","year":"1997","unstructured":"Sweet RA, Pollock BG, Mulsant BH et al (1997) Associations of plasma homovanillic acid with behavioral symptoms in patients diagnosed with dementia: a preliminary report. Biol Psychiatry 42:1016\u20131023. doi: 10.1016\/S0006-3223(97)00146-7","journal-title":"Biol Psychiatry"},{"key":"9851_CR29","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/gps.1569","volume":"21","author":"TJM Cammen van der","year":"2006","unstructured":"van der Cammen TJM, Tiemeier H, Engelhart MJ et al (2006) Abnormal neurotransmitter metabolite levels in Alzheimer patients with a delirium. Int J Geriatr Psychiatry 21:838\u2013845. doi: 10.1002\/gps.1569","journal-title":"Int J Geriatr Psychiatry"},{"key":"9851_CR30","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S0006-3223(97)00293-X","volume":"43","author":"MB Bowers","year":"1998","unstructured":"Bowers MB, Malison RT, Seibyl JP et al (1998) Plasma homovanillic acid and the dopamine transporter during cocaine withdrawal. Biol Psychiatry 43:278\u2013281. doi: 10.1016\/S0006-3223(97)00293-X","journal-title":"Biol Psychiatry"},{"key":"9851_CR31","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/0006-3223(90)90055-7","volume":"27","author":"I Degrell","year":"1990","unstructured":"Degrell I, Nagy E (1990) Correlations between cisternal CSF and plasma concentrations of HVA, MHPG, 5-HIAA, DA, and NA. Biol Psychiatry 27:1179\u20131182. doi: 10.1016\/0006-3223(90)90055-7","journal-title":"Biol Psychiatry"},{"key":"9851_CR32","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/mds.870110204","volume":"11","author":"Huntington Study Group","year":"1996","unstructured":"Huntington Study Group (1996) Unified Huntington\u2019s Disease Rating Scale. Reliability and consistency. Mov Disord 11:136\u2013142. doi: 10.1002\/mds.870110204","journal-title":"Mov Disord"},{"key":"9851_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.29.1.1","volume":"29","author":"I Shoulson","year":"1979","unstructured":"Shoulson I, Fahn S (1979) Huntington\u2019s disease. Clinical care and evaluation. Neurology 29:1\u20133","journal-title":"Neurology"},{"key":"9851_CR34","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1006\/mcpr.1993.1034","volume":"7","author":"JP Warner","year":"1993","unstructured":"Warner JP, Barron LH, Brock DJH (1993) A new polymerase chain reaction (PCR) assay for the trinucleotide repeat that is unstable and expanded on Huntington\u2019s disease chromosomes. Mol Cell Probes 7:235\u2013239. doi: 10.1006\/mcpr.1993.1034","journal-title":"Mol Cell Probes"},{"key":"9851_CR35","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.pnpbp.2007.01.005","volume":"31","author":"M Zumarraga","year":"2007","unstructured":"Zumarraga M, Davila R, Gonzales-Torres MA et al (2007) Inter- and intra-individual variability in the levels of plasma homovanillic acid in schizophrenic patients. Prog Neuro-Psychopharm Biol Psychiatry 31:713\u2013719. doi: 10.1016\/j.pnpbp.2007.01.005","journal-title":"Prog Neuro-Psychopharm Biol Psychiatry"},{"key":"9851_CR36","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0920-9964(93)90006-5","volume":"9","author":"R Labarca","year":"1993","unstructured":"Labarca R, Silva H, Jerez S et al (1993) Differential effects of haloperidol on negative symptoms in drug-na\u00efve schizophrenic patients: effects on plasma homovanillic acid. Schizophr Res 9:29\u201334. doi: 10.1016\/0920-9964(93)90006-5","journal-title":"Schizophr Res"},{"key":"9851_CR37","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0022-3956(01)00008-5","volume":"35","author":"ZJ Zhang","year":"2001","unstructured":"Zhang ZJ, Peet M, Ramchand CN et al (2001) Plasma homovanillic acid in untreated schizophrenia-relationship with symptomatology and sex. J Psychiatr Res 35:23\u201328. doi: 10.1016\/S0022-3956(01)00008-5","journal-title":"J Psychiatr Res"},{"key":"9851_CR38","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/BF02429064","volume":"145","author":"DH Hunneman","year":"1986","unstructured":"Hunneman DH, Jonas W, Gabriel M et al (1986) Effect of age on homovanillic and 4-hydroxy-3-methoxymandelic acid levels in plasma. Eur J Pediatr 145:555\u2013557. doi: 10.1007\/BF02429064","journal-title":"Eur J Pediatr"},{"key":"9851_CR39","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0893-133X(95)00158-A","volume":"15","author":"M Beuger","year":"1996","unstructured":"Beuger M, van Kammen DP, Kelley ME et al (1996) Dopamine turnover in schizophrenia before and after haloperidol withdrawal. CSF, plasma, and urine studies. Neuropsychopharmacology 15:75\u201386. doi: 10.1016\/0893-133X(95)00158-A","journal-title":"Neuropsychopharmacology"},{"key":"9851_CR40","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1093\/brain\/119.6.2085","volume":"119","author":"A Antonini","year":"1996","unstructured":"Antonini A, Leenders KL, Spiegel R et al (1996) Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington\u2019s disease. Brain 119:2085\u20132095. doi: 10.1093\/brain\/119.6.2085","journal-title":"Brain"},{"key":"9851_CR41","doi-asserted-by":"crossref","first-page":"7899","DOI":"10.1523\/JNEUROSCI.1396-07.2007","volume":"27","author":"T-A Tang","year":"2007","unstructured":"Tang T-A, Chen X, Liu J et al (2007) Dopaminergic signaling and striatal neurodegeneration in Huntington\u2019s disease. J Neurosci 27:7899\u20137910","journal-title":"J Neurosci"}],"container-title":["Neurochemical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-008-9851-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11064-008-9851-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-008-9851-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:36:05Z","timestamp":1559349365000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11064-008-9851-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,8]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["9851"],"URL":"https:\/\/doi.org\/10.1007\/s11064-008-9851-1","relation":{},"ISSN":["0364-3190","1573-6903"],"issn-type":[{"value":"0364-3190","type":"print"},{"value":"1573-6903","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,8]]}}}